These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
707 related articles for article (PubMed ID: 19654036)
21. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy. Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339 [TBL] [Abstract][Full Text] [Related]
22. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528 [TBL] [Abstract][Full Text] [Related]
23. New treatment options have changed the survival of patients with follicular lymphoma. Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674 [TBL] [Abstract][Full Text] [Related]
24. Uncontrolled-rate freezing of peripheral blood progenitor cells allows successful engraftment by sparing primitive and committed hematopoietic progenitors. Almici C; Ferremi P; Lanfranchi A; Ferrari E; Verardi R; Marini M; Rossi G Haematologica; 2003 Dec; 88(12):1390-5. PubMed ID: 14687993 [TBL] [Abstract][Full Text] [Related]
25. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide. Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404 [TBL] [Abstract][Full Text] [Related]
26. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity. Boiron JM; Dazey B; Cailliot C; Launay B; Attal M; Mazurier F; McNiece IK; Ivanovic Z; Caraux J; Marit G; Reiffers J Transfusion; 2006 Nov; 46(11):1934-42. PubMed ID: 17076849 [TBL] [Abstract][Full Text] [Related]
27. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. Ha CS; Cabanillas F; Lee MS; Tucker SL; McLaughlin P; Rodriguez MA; Younes A; Romaguera JE; Mesina OM; Cox JD Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):188-93. PubMed ID: 16111588 [TBL] [Abstract][Full Text] [Related]
28. Engraftment potential of peripheral and cord blood stem cells evaluated by a long-term culture system. Hirao A; Kawano Y; Takaue Y; Suzue T; Abe T; Sato J; Saito S; Okamoto Y; Makimoto A; Kawahito M Exp Hematol; 1994 Jun; 22(6):521-6. PubMed ID: 8187849 [TBL] [Abstract][Full Text] [Related]
29. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [TBL] [Abstract][Full Text] [Related]
30. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952 [TBL] [Abstract][Full Text] [Related]
31. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110 [TBL] [Abstract][Full Text] [Related]
32. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near? Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831 [TBL] [Abstract][Full Text] [Related]
33. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Leo E; Scheuer L; Schmidt-Wolf IG; Kerowgan M; Schmitt C; Leo A; Baumbach T; Kraemer A; Mey U; Benner A; Parwaresch R; Ho AD Eur J Haematol; 2004 Oct; 73(4):251-7. PubMed ID: 15347311 [TBL] [Abstract][Full Text] [Related]
34. Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy. McClanahan F; Hielscher T; Rieger M; Hensel M; Neben K; Hillengass J; Herfarth K; Ho AD; Witzens-Harig M Eur J Haematol; 2010 Jul; 85(1):11-9. PubMed ID: 20331739 [TBL] [Abstract][Full Text] [Related]
35. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999 [TBL] [Abstract][Full Text] [Related]
36. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517 [TBL] [Abstract][Full Text] [Related]
37. Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma. Hartmann JT; Meisinger I; Kröber SM; Weisel K; Klingel K; Kanz L Haematologica; 2006 Dec; 91(12 Suppl):ECR49. PubMed ID: 17194655 [TBL] [Abstract][Full Text] [Related]
38. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma. Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491 [TBL] [Abstract][Full Text] [Related]
39. Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma. Palomera L; Azaceta G; Varo MJ; Soria J; Gutierrez M Haematologica; 1998 Nov; 83(11):1045-6. PubMed ID: 9864929 [TBL] [Abstract][Full Text] [Related]
40. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Harjunpää A; Taskinen M; Nykter M; Karjalainen-Lindsberg ML; Nyman H; Monni O; Hemmer S; Yli-Harja O; Hautaniemi S; Meri S; Leppä S Br J Haematol; 2006 Oct; 135(1):33-42. PubMed ID: 16925574 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]